FDA approves generic version of Vumerity for relapsing MS
Zydus Lifesciences received final approval from the U.S. Food and Drug Administration (FDA) to market a generic version of…
Articles by Patricia Inacio, PhD
New cladribine formula continues advance to human trial for MS
Bionxt Solutions has launched the final animal study needed to prepare for human testing of BNT23001, its sublingual version…
With new data, Quantum moves closer to launching trial of Lucid-MS
Quantum Biopharma says it is closer to initiating a Phase 2 clinical trial — one involving people living with…
New generic version of Zeposia could lower cost of MS treatment
A generic formulation of Zeposia (ozanimod), which won tentative approval for treating multiple sclerosis (MS) from the U.S.
New blood test for MS receives major commercialization funding
Octave Bioscience has raised $35.6 million in funding to continue marketing its multiple sclerosis (MS) disease activity…
New partnership bringing MS biosimilar drug to MENA region
Three biosimilar drugs — approved versions of brand-name therapies that have no clinically meaningful differences compared with their reference products…
Quantum prepares for Phase 2 trial of oral therapy Lucid-MS
An oral treatment that could repair nerve damage in multiple sclerosis (MS) is a step closer to a Phase 2…
First person with MS gets ‘off-the-shelf’ CAR T-cell therapy
A person with multiple sclerosis (MS) has for the first time been treated with an “off-the-shelf” CAR T-cell therapy…
Sex-related gap found for use of DMTs in MS patients ages 18-40
Despite evidence supporting the safety of disease-modifying therapies (DMTs) during pregnancy, women with multiple sclerosis (MS) in their childbearing…
A&W Canada wants to beat MS ‘one burger at a time’ this August
A&W Canada’s annual Burgers to Beat MS Day is returning for its 17th year to raise funds for MS…
Virginia law firm to host fundraiser for MS care, research
The law firm Kalfus & Nachman will host a special event to raise funds for multiple sclerosis (MS)…
Sleep quality worse for MS patients than healthy people, study finds
While people with multiple sclerosis (MS) seem to get a similar quantity of sleep relative to individuals without the…
First clinical trial of remyelination therapy PTD802 cleared in the UK
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Pheno Therapeutics to initiate a first-in-human Phase 1…
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Sanofi’s BTK inhibitor candidate tolebrutinib for…
Fellowship will fund research into myelin sheath repair in MS
A PhD student at the UMass Chan Medical School will use funding from a newly awarded fellowship to advance his…
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS
The U.S Food and Drug Administration (FDA) authorized an investigational new drug application from Synaptogenix, clearing the company to…
Centers of Excellence added to grow Neural Sleeve use in MS care
Cionic has added three renowned institutions on the East Coast to its national Centers of Excellence program, a move…
Foralumab eases inflammation in 80% of nonactive SPMS patients
Most patients with nonactive secondary progressive multiple sclerosis (SPMS) who took foralumab nasal spray for at least six months…
MS healthcare experts to gather at 38th CMSC meeting in Nashville
Renowned experts in multiple sclerosis (MS) healthcare, research, and advocacy will again gather at the annual meeting of the Consortium…
PoNS device made available to US veterans through new collaboration
Helius Medical Technologies is collaborating with Lovell Government Services to make its PoNS device — designed to improve walking…
Clinical trial to test multiple Lucid-MS doses in healthy volunteers
FSD Pharma has entered an agreement to launch a Phase 1 clinical trial that will test multiple ascending doses of…
Juvisé to market, develop Ponvory outside North America
The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS)…
Neurostimulator to repair myelin in RRMS named breakthrough device
The U.S. Food and Drug Administration has designated SetPoint Medical’s neurostimulator a breakthrough device for the treatment of…
Fatigue predicts worse health-related quality of life in RRMS
Fatigue is a significant predictor of worse health-related quality of life in adults with relapsing-remitting multiple…
Tysabri biosimilar Tyruko now available in Germany for RRMS
Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS).
Florida’s Team Rocco hopes to raise $100K in Walk MS on Feb. 25
Rocco Mangel, the founding partner of Rocco’s Tacos & Tequila Bar, is joining the Walk MS: West Palm Beach…
MS treatment Ponvory wins patent protection in US, to run until 2042
The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the…
People living with HIV significantly less likely to develop MS: Study
Living with the human immunodeficiency virus (HIV) is linked to a significantly lower rate of developing multiple sclerosis (MS)…
Sudo raises $116M to develop TYK2 inhibitors for MS, other diseases
Sudo Biosciences has raised $116 million in a Series B financing to support the clinical development of two inhibitors…
Tracking brain changes in early MS can predict odds of progression
The rate of brain atrophy, or shrinkage, and changes in brain lesion volume in the first years of treatment with…